Trial failures end latest hope for Roche’s Alzheimer’s drug

An experimental Alzheimer’s disease medicine from Roche failed two large Phase 3 clinical trials, a major setback to the Swiss company’s yearslong effort to prove the drug might slow the progression of the disease.